Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Central Pacific Financial

Evercore

Expeditors International of Washington

FactSet Research Systems

Hyster-Yale Materials Handling

Kellogg

ManpowerGroup

Masco

Materion

National Bank Hlds

Watts Water Technologies

All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 11.2% and a median of 5.7%.

14 Upcoming Dividend Increases Including Johnson & Johnson

Bemis Company

These two healthcare companies boast stellar dividend records, even when the market plunges.

2 of the Safest Dividend Stocks to Hold During a Market Crash

Emergent BioSolutions

The FDA is holding more than 100 million Johnson & Johnson Covid-19 vaccine doses for further testing, Emergent BioSolutions CEO Robert Kramer told lawmakers Wednesday.

Emergent CEO says FDA is holding over 100 million J&J Covid vaccine doses for further testing after botched doses

Some employees at the Emergent BioSolutions plant in Baltimore failed to shower or change clothes, according to a memo released Wednesday by a key House committee.

Employees at plant that ruined millions of J&J Covid vaccine doses failed to shower, change clothes

Johnson and Johnson (NYSE: JNJ) has joined hands with India-based Biological E Limited to manufacture its COVID-19 vaccine, alongside Biological E's COVID-19 vaccine candidate, which could boost the country's overall supplies amid a shortage. "The infrastructure and plants are completely separate for both the products and we will be producing both independent of each other," said Mahima Datla, Managing Director & CEO of Biological E, in a text message, declining to give any timeline or other details.

India's Biological E To Make Johnson & Johnson's COVID-19 Shots: Reuters

Coca-Cola

Microsoft

Procter & Gamble

York Water

Like the sun rising in the East, income investors can count on these rock-solid dividend stocks.

These Are the Safest Dividend Stocks in the World

And there's an important lesson to be learned about how it achieved this impressive return.

Step Aside, Dogecoin -- This Stock Has Delivered a Gain of Over 1,100,000%

Cerecor

CRISPR Therapeutics

Horizon Pharma

Eli Lilly

Schrodinger 

Takeda Pharmaceutical

Here are seven biotech stocks with loads of innovation and plenty of catalysts to make money for smart investors. The post 7 Best Biotech Stocks To Buy in 2021 as Innovation Takes Center Stage appeared first on InvestorPlace.

7 Best Biotech Stocks To Buy in 2021 as Innovation Takes Center Stage

AstraZeneca

BioNTech SE

Moderna

Pfizer

Vaccine makers, including Pfizer, Johnson & Johnson, AstraZeneca, and BioNTech, are set to make billions for many years to come.

Vaccine Makers Will Make Billions For Years To Come: Which One To Buy Now

Johnson & Johnson ( JNJ , Financial) is one of the largest holdings in my personal portfolio, as the company's business model has provided for nearly six decades of dividend growth. This qualifies the company as a Dividend King.

Johnson & Johnson: A Cornerstone Investment

Clorox

Genuine Parts

Hormel Foods

Five stocks with rising dividends, plus how to find more.

5 Dependable Dividend Stocks to Help You Crush Inflation

Arrowhead Pharmaceuticals

Janssen Pharmaceuticals Inc, part of Johnson & Johnson (NYSE: JNJ), has delivered written notice of its intent to exercise its option right for ARO-JNJ1. Receipt of the option notice earns Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) a $10 million option exercise fee.

Arrowhead Receives $10M Option Exercise Fee From Janssen

Those plans come after the White House said it would send 60 million doses of AstraZeneca's Covid vaccine to countries in need

Biden to say U.S. will send 20 million Pfizer, Moderna or J&J vaccine doses abroad by end of June

Viatris

Vanguard High Dividend Yield ETF

Verizon

Exxon Mobil

The S&P 500 is now hitting and crossing over 4,200+ and valuation continues to be a struggle in the stock market. My dividend stock portfolio was burnt by dividend cuts in 2020 and lost over $800+ in forward dividend income.

Dividend Stock Purchase: Lanny's April 2021 Summary

Hershey

Lockheed Martin

NIKE

Raytheon Technologies

Union Pacific

This article series presents upcoming ex-dividend dates. We provide a summary table with relevant data and key statistics, including the next payout and pay date.

Upcoming Ex-Dividend Dates: May 18-31, 2021

COPENHAGEN, Denmark, May 17, 2021 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that its partner Johnson & Johnson is supporting efforts by the World Health Organization (WHO) to prevent further spread of Ebola in West Africa through the donation of up to 200,000 courses of the Johnson & Johnson Ebola vaccine regimen. The Johnson & Johnson Ebola vaccine regimen includes Mvabea®, which was developed and manufactured by Bavarian Nordic. The vaccine regimens are being made available through an early access clinical program directed by the WHO and national governments, and the first doses were administered last week in Sierra Leone.

Ebola Vaccine Regimen from Johnson & Johnson and Bavarian Nordic Supports World Health Organization in Efforts to Prevent Spread of Ebola in West Africa

Cisco Systems

JPMorgan Chase & Co

TimkenSteel

Travelers

Walgreens

Two new breakout stocks for Week 20 with better than 10% short-term upside potential. This past week ADTN gained +11.5% in less than 5 days with CARG gaining +8.9%. 3 stocks were positive 2 negative at the close +1.23% for the portfolio.

Week 20 MDA Breakout Stocks - May 2021: Short-Term Picks To Give You An Edge

News for Johnson & Johnson Stock (JNJ)